Is Akari Therapeutics Plc (AKTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 28.3% / 30% | 22.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 28.3% / 33% | 22.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 6.4% / 33% | 5.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 28.3% / 33% | 22.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 6.4% / 33% | 5.1% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -197.2% | |
| Return on Assets (ROA) | -34.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $3M |
| Debt-to-Equity | 9.8 |
| Current Ratio | 0.2 |
| Total Assets | $51M |
Price & Trading
| Last Close | $0.14 |
| 50-Day MA | $0.23 |
| 200-Day MA | $0.64 |
| Avg Volume | 419K |
| Beta | 0.3 |
|
52-Week Range
$0.13
| |
About Akari Therapeutics Plc (AKTX)
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Akari Therapeutics Plc (AKTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Akari Therapeutics Plc is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Akari Therapeutics Plc's debt ratio?
Akari Therapeutics Plc's debt ratio is 28.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.4%.
What are Akari Therapeutics Plc's key financial metrics?
Akari Therapeutics Plc has a market capitalization of $6M, trailing P/E ratio of inf. Return on equity stands at -197.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.